Tags

Type your tag names separated by a space and hit enter

Buprenorphine treatment for opioid use disorder: recent progress.
Expert Rev Clin Pharmacol 2019; 12(8):791-803ER

Abstract

Introduction: Opioid use disorder (OUD) has risen globally and is exerting an enormous toll on public health in many countries, particularly in the United States (US). Buprenorphine (BUP) has become one of the mainstays of pharmacological treatment for OUD and newer delivery methods have been developed to improve its effectiveness in treatment. Areas covered: We provide a review of BUP products available for OUD, with a focus on the newer long-acting formulations. A literature search was conducted using PubMed, Google Scholar, and ClinicalTrials.gov to find randomized clinical trials of long-acting BUP products. Four randomized clinical trials were found: two with BUP implant and two with subcutaneous injectable BUP. Expert opinion: In these clinical trials, new BUP formulations were found to be non-inferior to sublingual (SL) BUP and more effective than placebo in reducing opioid use. Longer-acting formulations can improve flexibility in dosing but superiority over existing SL BUP with regards to outcomes needs to be ascertained. There is a need for more comparative studies between longer-acting BUP formulations and currently available SL BUP. Future studies should also include other clinically meaningful outcomes such as quality of life measures, long-term remission rates, and cost-effectiveness.

Authors+Show Affiliations

a VA Connecticut Healthcare System, VA Connecticut Health System West Haven Campus , West Haven , CT , USA. b School of Medicine, Department of Psychiatry, Yale University , New Haven , CT , USA.b School of Medicine, Department of Psychiatry, Yale University , New Haven , CT , USA.a VA Connecticut Healthcare System, VA Connecticut Health System West Haven Campus , West Haven , CT , USA. b School of Medicine, Department of Psychiatry, Yale University , New Haven , CT , USA.a VA Connecticut Healthcare System, VA Connecticut Health System West Haven Campus , West Haven , CT , USA. b School of Medicine, Department of Psychiatry, Yale University , New Haven , CT , USA.

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

31232604

Citation

Parida, Suprit, et al. "Buprenorphine Treatment for Opioid Use Disorder: Recent Progress." Expert Review of Clinical Pharmacology, vol. 12, no. 8, 2019, pp. 791-803.
Parida S, Carroll KM, Petrakis IL, et al. Buprenorphine treatment for opioid use disorder: recent progress. Expert Rev Clin Pharmacol. 2019;12(8):791-803.
Parida, S., Carroll, K. M., Petrakis, I. L., & Sofuoglu, M. (2019). Buprenorphine treatment for opioid use disorder: recent progress. Expert Review of Clinical Pharmacology, 12(8), pp. 791-803. doi:10.1080/17512433.2019.1635454.
Parida S, et al. Buprenorphine Treatment for Opioid Use Disorder: Recent Progress. Expert Rev Clin Pharmacol. 2019;12(8):791-803. PubMed PMID: 31232604.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Buprenorphine treatment for opioid use disorder: recent progress. AU - Parida,Suprit, AU - Carroll,Kathleen M, AU - Petrakis,Ismene L, AU - Sofuoglu,Mehmet, Y1 - 2019/06/30/ PY - 2019/6/25/pubmed PY - 2019/8/20/medline PY - 2019/6/25/entrez KW - Buprenorphine KW - implant KW - injection KW - long-acting KW - subcutaneous KW - sublingual KW - transmucosal SP - 791 EP - 803 JF - Expert review of clinical pharmacology JO - Expert Rev Clin Pharmacol VL - 12 IS - 8 N2 - Introduction: Opioid use disorder (OUD) has risen globally and is exerting an enormous toll on public health in many countries, particularly in the United States (US). Buprenorphine (BUP) has become one of the mainstays of pharmacological treatment for OUD and newer delivery methods have been developed to improve its effectiveness in treatment. Areas covered: We provide a review of BUP products available for OUD, with a focus on the newer long-acting formulations. A literature search was conducted using PubMed, Google Scholar, and ClinicalTrials.gov to find randomized clinical trials of long-acting BUP products. Four randomized clinical trials were found: two with BUP implant and two with subcutaneous injectable BUP. Expert opinion: In these clinical trials, new BUP formulations were found to be non-inferior to sublingual (SL) BUP and more effective than placebo in reducing opioid use. Longer-acting formulations can improve flexibility in dosing but superiority over existing SL BUP with regards to outcomes needs to be ascertained. There is a need for more comparative studies between longer-acting BUP formulations and currently available SL BUP. Future studies should also include other clinically meaningful outcomes such as quality of life measures, long-term remission rates, and cost-effectiveness. SN - 1751-2441 UR - https://www.unboundmedicine.com/medline/citation/31232604/Buprenorphine_treatment_for_opioid_use_disorder:_recent_progress_ L2 - http://www.tandfonline.com/doi/full/10.1080/17512433.2019.1635454 DB - PRIME DP - Unbound Medicine ER -